---
title: "FRES: Record financial results, reduced CapEx, and strong project pipeline drive robust shareholder returns"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294853908.md"
description: "Record H1 2026 results with revenues, gross profit, and EBITDA more than doubling year-over-year, driven by higher metal prices and strong operations. CapEx guidance reduced, major projects advancing, and $1 billion in dividends paid while maintaining a strong cash position.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-04T17:16:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294853908.md)
  - [en](https://longbridge.com/en/news/294853908.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294853908.md)
generator: "portal-rs"
---

# FRES: Record financial results, reduced CapEx, and strong project pipeline drive robust shareholder returns

Record H1 2026 results with revenues, gross profit, and EBITDA more than doubling year-over-year, driven by higher metal prices and strong operations. CapEx guidance reduced, major projects advancing, and $1 billion in dividends paid while maintaining a strong cash position.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [FRES.UK](https://longbridge.com/en/quote/FRES.UK.md)

## Related News & Research

- [FRES: Record revenue and profit growth in 1H26, with strong outlook and disciplined capex](https://longbridge.com/en/news/294776511.md)
- [CXI: Payments revenue soared 54% in Q3, driving overall growth despite softer banknotes](https://longbridge.com/en/news/298613141.md)
- [Finmo lifts office capacity by 50% with new Suntec City HQ](https://longbridge.com/en/news/298396377.md)
- [Weekly Recap: AI monetization pressure and HK$100.3m buyback](https://longbridge.com/en/news/298142631.md)
- [Blau Farmacêutica: Growth driven by biosimilars, mAbs, and operational efficiency boosts margins and global reach](https://longbridge.com/en/news/298370499.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**